CD274 and acute myeloid leukemia: In general, resistance‐types in AML LSC can be divided into: (a) intrinsic stem cell resistance common to LSC in all AML subclones, (b) acquired (secondary) resistance mediated by additional (acquired) somatic mutations, loss of tumor suppressor antigens, or loss of target‐antigens, (c) niche‐induced resistance, and (d) immunologic resistance induced by expression of certain checkpoint molecules, like PD‐L1, on AML LSC (Table 3).